Not-celiac Gluten (Wheat) Sensitivity Clinical Trial
Official title:
Randomized Double-Blind Placebo-Controlled Trial (Wheat vs Placebo) in Wheat Sensitive Patients for Evaluation of Bio-Markers of a Single Referred Symptom (Bloating & Swelling)
Aim of the investigators' study is to evaluate one of the symptoms described by patients
affected with the so-called "not-celiac wheat sensitivity" (NCWS). NCWS patients may be
defined as ones, neither celiac or allergic to wheat, who develop symptoms following wheat
consumption and improve on Gluten Free Diet (GFD). Among these, patients often report the
appearance of bloating and abdominal pain, and, sometimes, swelling of fingers and face,
shortly after ingestion of wheat. They also refer that swelling tends to last for some hours
and then to disappear on GFD. To our knowledge, this disorder has never been investigated
neither proved.
For the investigators' research, the investigators selected adult patients, both genders,
affected with NCWS. Diagnostic criteria include: 1) symptoms disappearance on GFD, 2)
testing negative for celiac disease [anti-tTG and EMA, and with biopsy Marsh 0-1] and wheat
allergy [serum specific IgE for wheat], 3) positive response to a double-blind
placebo-controlled challenge (DBPC) with wheat or placebo.
Patients will be recruited among subjects referring, as outpatients, to the Department of
Internal Medicine, 'Giovanni Paolo II' Hospital of Sciacca (Agrigento), and of Internal
Medicine of the University of Palermo, from January 2012 to October 2013. The investigators
will include patients referring for functional dyspepsia and/or irritable bowel syndrome
(IBS)-like symptoms. All recruited patients must report body's swelling immediately after
wheat ingestion. In all recruited patients, NCWS diagnosis was posed during the previous
years, according to the above mentioned criteria.
Patients, all on GFD for at least 30 days, will undergo to another DBPC with wheat or
placebo (xylose), performed by administering capsules coded as A or B containing wheat or
xylose, respectively. Capsules A or B will be administered once, and then, after 1 week of
washout, patients received the other capsules, given once too. Before and 2 hours after
every challenge, patients will undergo a complete medical examination (measurement of body
weight, height, body mass index [BMI], waist circumference, diameter of thighs, legs, arms,
and fingers), and we will perform bioelectrical impedance analysis and collect blood
sampling, for identification of possible markers (bioelectrical, immunologic, hormonal, etc)
that may help to demonstrate and explain mechanisms of examined symptom.
Gluten is the most important protein component of some grains, notably wheat, rye, and
barley, which are the basis for a variety of wheat-derived alimentary products consumed
throughout the world (bread, pasta, pizza etc). However the "engineering" of
gluten-containing grains created the conditions for human diseases related to gluten
exposure. These forms of gluten intolerance represent a heterogeneous set of conditions,
including celiac disease, wheat allergy and gluten sensitivity, that, combined, seems to
affect about 10% of the general population. The frequency of not-celiac gluten sensitivity
is however still unknown, even though it is possible that this condition have been
undiagnosed and under-diagnosed by the physicians for a long time. The immune responsiveness
to wheat antigens represents a complex process, and its establishment and maintenance are
not completely elucidated. The most frequent diseases caused by wheat ingestion are T
cell-mediated disorders, i.e. celiac disease and immunoglobulin E (IgE)-mediated allergic
reactions. However, besides celiac disease and wheat allergy, there are cases of gluten
reactions in which neither autoimmune nor IgE-mediated allergic mechanisms are involved.
These are generally defined as gluten sensitivity. Some subjects, who experience symptoms
when eating gluten-containing products and show improvement when following a gluten-free
diet, may have gluten sensitivity instead of celiac disease or wheat allergy. Gluten
sensitivity patients are unable to tolerate gluten and develop an adverse reaction when
eating gluten, that, usually, and differently from celiac disease, does not lead to small
intestinal damage. Gastrointestinal symptoms in gluten sensitivity patients may resemble
those associated with celiac disease, but the overall clinical picture is generally less
severe and is not accompanied by the occurrence of autoantibodies (i.e. anti-tissue
transglutaminase, tTG, or anti-endomysium, EMA) or autoimmune disease (i.e. Hashimoto's
thyroiditis). Typically, the diagnosis is made by exclusion, and an elimination diet and an
"open challenge" (i.e., the monitored reintroduction of gluten-containing foods) are most
often used to evaluate whether health improves or worsen with the elimination or
reintroduction of gluten in the diet, respectively.
As it is not known what cereals components determine the symptoms in the so called gluten
sensitivity patients, we prefer to define this condition as "wheat sensitivity" instead of
"gluten sensitivity".
Wheat sensitivity can cause both gastrointestinal and extra-intestinal symptoms; among the
latter, the patients often reported body's swelling (hands', fingers', arms' , face's
swelling).
This study has two major aims:
1. Evaluation of the effective dependence from the wheat ingestion of the clinical
alterations presented by patients with diagnosed gluten sensitivity, with particular
attention to abdominal bloating and body's swelling. The study will be done after a
period of gluten-free diet (at least 30 days), using a double-blind placebo-controlled
challenge with wheat or placebo (xylose), performed by administering capsules coded as
A or B containing wheat or xylose, respectively. Capsules A or B will be administered
once, and then, after 1 week of washout, the patients received the other capsules,
given once too.
2. Before and 2 hours after every challenge, patients will undergo a complete medical
examination, and The investigators will perform bioelectrical impedance analysis and
collect blood sampling, for identification of possible markers that may be of help to
demonstrate and explain the mechanisms of the examined symptom.
;
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic